A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPAND
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Jun 2018 Results assessing the impact of Siponimod on Confirmed Disability Progression (CDP) in patients with/without relapses to uncouple the treatment effect on CDP from the effect of relapses presented at the 4th Congress of the European Academy of Neurology
    • 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
    • 27 Apr 2018 Results of subgroup analysis exploring the effect of Siponimod on neurofilament light chain levels in blood of patients with SPMS presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top